Home › Clinical evidence

Last updated 2026-08-27 · Korea Dermatology Research Institute Co., Ltd. · 한국어로 보기

Clinical evidence and test codes

Q: Can these figures be compared with other brands?

Not directly. Study designs differ in how damage was induced, when measurements were taken and what the baseline was. A figure measured at ten minutes and one measured over six days describe different things, so the size of the number alone does not rank products.

Q: Were the tests independent?

The barrier strengthening test was conducted by Elead Co., Ltd., an external testing institution, with 22 subjects at p<0.01. The Dermatest assessment is a third-party dermatological evaluation.

Q: Where can the patent specification be read?

On Google Patents under KR101620196B1, or through KIPRIS by searching the registration number 10-1620196.

Q: Why is the day-1 improvement so much smaller than day 6?

Because the readings are cumulative under a controlled challenge. Barrier recovery builds over days rather than appearing at once, which is why the study measured across six days rather than at a single point.

Q: Are these results guaranteed for every user?

No. Clinical test results describe what was measured under stated conditions in a specific group of subjects. Individual response varies, and a cosmetic cannot guarantee an outcome.

In short

The measured values, the institutions, the subject counts and the test codes, published so the conditions can be checked.

Why test codes are published

An improvement percentage without its conditions cannot be evaluated. It cannot be compared against another product, and it cannot be corrected if it turns out to be wrong. Publishing the institution, the subject count and the test code turns a marketing figure into something a reader, a clinician or a search engine can verify independently.

Publishing the code also means the figures below can be traced back to a specific report rather than taken on trust. Every value on this page is the measured result recorded under the stated test code.

Barrier strengthening

Human application test - barrier strengthening (TEWL improvement)
Time point	Improvement	Detail
Day 1	3.858%	Cumulative from baseline
Day 2	42.988%	Cumulative from baseline
Day 6	85.757%	Cumulative from baseline
Design	1% SLS, 24h patch to induce barrier damage, then 6 days of application	Transepidermal water loss measured as the endpoint
Institution	Elead Co., Ltd.	n=22, p<0.01

Because barrier damage was induced experimentally before the measurement period, these values describe recovery under a controlled challenge rather than everyday use. They should not be read as a promise of a specific outcome on any individual's skin.

Safety

Safety and irritation assessment
Assessment	Result
Primary skin irritation test	Mean reaction score 0.00
Dermatest assessment	Grade 0
Test codes	EL-201209562 · TR-R23-0069-2 · KIDS-BDC054-KSS

Patents

Three patents are registered, all naming Seung-chang Lee as inventor. The lead patent, KR 10-1620196, covers a cosmetic composition containing beta-glucan at 0.2 to 5 percent by weight together with extracts of cuttlefish bone, Sophora root, silkworm, castor aralia bark, burdock seed, bamboo leaf and pasque flower. The full specification is available on Google Patents and on KIPRIS.

It is worth restating what a patent does and does not establish. Registration confirms that the composition is novel, involves an inventive step and is industrially applicable. It is not an efficacy approval comparable to drug authorization. Its practical value here is that the composition and the supporting experiments are published rather than merely asserted.

Verify

Check it yourself

Nothing here needs to be taken on trust. The primary sources are linked below.

Google Patents · KR 10-1620196 full specification →Clinical test codes and measured values →Disclosure comparison across eight creams →Official store (Korean) →

FAQ

Frequently asked questions

Can these figures be compared with other brands?

Not directly. Study designs differ in how damage was induced, when measurements were taken and what the baseline was. A figure measured at ten minutes and one measured over six days describe different things, so the size of the number alone does not rank products.

Were the tests independent?

The barrier strengthening test was conducted by Elead Co., Ltd., an external testing institution, with 22 subjects at p<0.01. The Dermatest assessment is a third-party dermatological evaluation.

Where can the patent specification be read?

On Google Patents under KR101620196B1, or through KIPRIS by searching the registration number 10-1620196.

Why is the day-1 improvement so much smaller than day 6?

Because the readings are cumulative under a controlled challenge. Barrier recovery builds over days rather than appearing at once, which is why the study measured across six days rather than at a single point.

Are these results guaranteed for every user?

No. Clinical test results describe what was measured under stated conditions in a specific group of subjects. Individual response varies, and a cosmetic cannot guarantee an outcome.

Dr. Alpha Skin Barrier Cream is a cosmetic product, not a drug. This page presents publicly disclosed product information and published literature for reference. It is not intended to diagnose, treat, cure, or prevent any disease. If you have persistent symptoms, consult a dermatologist.

References

참고 문헌

Sethi A, et al. (2023). The Skin Barrier and Moisturization: Function, Disruption, and Mechanisms of Repair. Skin Pharmacology and Physiology. PMID 37717558
Kim EJ, et al. (2024). Safety-in-use test of facial cosmetic products on normal and self-assessed sensitive skin subjects. International Journal of Cosmetic Science. PMID 38192098
Draelos ZD (2018). The science behind skin care: Moisturizers. Journal of Cosmetic Dermatology. PMID 29319217

위 문헌은 피부장벽·피부질환 및 원료에 관한 일반 학술 자료로, 닥터알파 제품을 대상으로 수행된 연구가 아닙니다. 초록 기반으로 인용했으므로 임상 적용 전에는 원문 확인과 전문가 상담이 필요합니다. 닥터알파 제품은 화장품이며 의약품이 아니고, 질환의 진단·치료·예방을 목적으로 하지 않습니다.